*Commentary* **Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials**

**Rayeil J. Chua 1, Rupert Capiña 1 and Hezhao Ji 1,2,\***


 **\*** Correspondence: hezhao.ji@phac-aspc.gc.ca; Tel.: +1-204-789-6521

**Abstract:** HIV/AIDS is a global public health crisis that is ye<sup>t</sup> to be contained. Effective managemen<sup>t</sup> of HIV drug resistance (HIVDR) supported by close resistance monitoring is essential in achieving the WHO 95-95-95 targets, aiming to end the AIDS epidemic by 2030. Point-of-care tests (POCT) enable decentralized HIVDR testing with a short turnaround time and minimal instrumental requirement, allowing timely initiation of effective antiretroviral therapy (ART) and regimen adjustment as needed. HIVDR POCT is of particular significance in an era when ART access is scaling up at a global level and enhanced HIVDR monitoring is urgently needed, especially for low-to-middle-income countries. This article provides an overview of the currently available technologies that have been applied or potentially used in HIVDR POCT. It may also benefit the continued research and development efforts toward more innovative HIVDR diagnostics.

**Keywords:** HIV; drug resistance; point-of-care test; resource-limited setting
